Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism
• By Ayisha Sharma
The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.
Several Firms Have Struggled To Develop Successful Glioma Drugs • Source: Shutterstock
Les Laboratoires Servier is determined to tackle the challenging glioma space with a cancer metabolism-based asset gained through its acquisition of Agios Pharmaceuticals, Inc.’ oncology portfolio, new executive Walid Kamoun told Scrip.
Kamoun was appointed global head of the French firm’s R&D Oncology in April, bringing 20 years of industry experience. He...
